miR-7975对口腔鳞状细胞癌恶性表型的影响

doi:10.13591/j.cnki.kqyx.2025.07.003

摘要/Abstract

摘要：

目的探究miR-7975对口腔鳞状细胞癌(oral squamous cell carcinoma,OSCC)恶性表型的影响及可能机制。方法本研究通过实时定量逆转录PCR实验(real-time quantitative reverse transcription PCR,qRT-PCR)比较了miR-7975在不同口腔细胞系中的表达水平。在OSCC细胞系HSC3及HN4中分别转染miR-7975 mimic以及miR-7975 inhibitor,利用集落形成实验、CCK8实验、Transwell实验及细胞划痕实验探究miR-7975对OSCC细胞恶性表型的影响。通过蛋白质免疫印迹实验(Western blot)研究上皮-间充质转化(epithelial-mesenchymal transition,EMT)及RAS/ERK信号通路相关蛋白表达水平的变化。通过裸鼠成瘤实验进一步验证miR-7975对体内成瘤的影响。结果 OSCC细胞中miR-7975表达下调。miR-7975过表达降低了OSCC细胞的增殖、迁移以及侵袭能力。相反,miR-7975表达下降则提高了OSCC细胞的增殖、迁移以及侵袭能力。过表达miR-7975后EMT相关蛋白E-cadherin表达上调,而N-cadherin、Vimentin、β-catenin、Snail和Slug则下降,RAS/ERK信号通路相关蛋白表达增多。miR-7975表达下降后EMT及RAS/ERK信号通路相关蛋白表达的变化相反。相比于对照组,过表达miR-7975后裸鼠皮下的成瘤体积及质量明显小于对照组,miR-7975表达下降后体内成瘤体积和质量明显增大。结论 miR-7975通过调控EMT及RAS/ERK信号通路,抑制OSCC的增殖、迁移和侵袭能力,从而发挥抑癌作用。

关键词: 口腔鳞状细胞癌, miR-7975, 上皮-间充质转化, RAS/ERK信号通路

Abstract:

Objective To investigate the effect of miR-7975 on the malignant phenotype of oral squamous cell carcinoma (OSCC) and its potential mechanisms. Methods This study compared the expression levels of miR-7975 in different oral cell lines by qRT-PCR. miR-7975 mimic and miR-7975 inhibitor were transfected into OSCC cell lines HSC3 and HN4 respectively. Colony formation assay, CCK8 assay, Transwell assay, and wound healing assay were conducted to evaluate the effects of miR-7975 on the malignant phenotype of OSCC cells. Western blot was employed to analyze changes in the expression of EMT related proteins and proteins associated with the RAS/ERK signaling pathway. Subcutaneous tumor model of nude mice was used to further validate the tumorigenic effect of miR-7975 in vivo. Results The expression of miR-7975 was downregulated in OSCC cells. Overexpression of miR-7975 reduced the proliferation, migration, and invasion abilities of OSCC cells, whereas downregulation of miR-7975 enhanced these abilities. After miR-7975 overexpression, the expression of the EMT-related protein E-cadherin was upregulated, while N-cadherin, Vimentin, β-catenin, Snail, and Slug were downregulated. Additionally, the expression of proteins related to the RAS/ERK signaling pathway increased. Conversely, the expression of EMT and RAS/ERK signaling pathway-related proteins showed opposite changes when miR-7975 was downregulated. Compared to the control group, the volume and weight of tumors formed in nude mice were significantly smaller after miR-7975 overexpression, while they were significantly larger when miR-7975 expression was reduced. Conclusion miR-7975 exerts its tumor-suppressive effects by inhibiting the proliferation, migration, and invasion of OSCC through the regulation of EMT and the RAS/ERK signaling pathway.

Key words: oral squamous cell carcinoma, miR-7975, epithelial-mesenchymal transition, RAS/ERK signaling pathway

中图分类号:

R739.85

高腾, 赵振远, 赵梦然, 刘婕, 宋晓萌. miR-7975对口腔鳞状细胞癌恶性表型的影响[J]. 口腔医学, 2025, 45(7): 495-501.

GAO Teng, ZHAO Zhenyuan, ZHAO Mengran, LIU Jie, SONG Xiaomeng. The effect of miR-7975 on the malignant phenotype of oral squamous cell carcinoma[J]. Stomatology, 2025, 45(7): 495-501.

图/表 7

图1

图2

图3

图4

图5

图6

图7

参考文献 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2]	D'Souza S, Addepalli V. Preventive measures in oral cancer: An overview[J]. Biomed Pharmacother, 2018, 107: 72-80. doi: S0753-3322(18)33634-5 pmid: 30081204
[3]	Chattopadhyay I, Verma M, Panda M. Role of oral microbiome signatures in diagnosis and prognosis of oral cancer[J]. Technol Cancer Res Treat, 2019, 18: 1533033819867354.
[4]	Struckmeier AK, Buchbender M, Lutz R, et al. Improved recurrence rates and progression-free survival in primarily surgically treated oral squamous cell carcinoma-results from a German tertiary medical center[J]. Clin Oral Investig, 2024, 28(5): 262.
[5]	Lu TX, Rothenberg ME. microRNA[J]. J Allergy Clin Immunol, 2018, 141(4): 1202-1207. doi: S0091-6749(17)31593-2 pmid: 29074454
[6]	Boehm M, Slack FJ. microRNA control of lifespan and metabolism[J]. Cell Cycle, 2006, 5(8): 837-840. doi: 10.4161/cc.5.8.2688 pmid: 16627994
[7]	Carleton M, Cleary MA, Linsley PS. microRNAs and cell cycle regulation[J]. Cell Cycle, 2007, 6(17): 2127-2132. doi: 10.4161/cc.6.17.4641 pmid: 17786041
[8]	Adereh A, Amini P, Fateh A, et al. Loc646329 sponges miR-21 to reduce RAS/MAP kinase signaling pathway in oral squamous cell carcinoma (OSCC)[J/OL]. Naunyn Schmiedeberg’s Arch Pharmacol, 2024[2025-03-03].https://doi.org/10.1007/s00210-024-03671-x.
[9]	Huang F, Xin C, Lei KX, et al. Noncoding RNAs in oral premalignant disorders and oral squamous cell carcinoma[J]. Cell Oncol (Dordr), 2020, 43(5): 763-777. doi: 10.1007/s13402-020-00521-9 pmid: 32495292
[10]	Shi BX, Ma C, Liu GL, et al. miR-106a directly targets LIMK1 to inhibit proliferation and EMT of oral carcinoma cells[J]. Cell Mol Biol Lett, 2019, 24: 1. doi: 10.1186/s11658-018-0127-8 pmid: 30873211
[11]	Zheng Y, Song A, Zhou Y, et al. Identification of extracellular vesicles-transported miRNAs in Erlotinib-resistant head and neck squamous cell carcinoma[J]. J Cell Commun Signal, 2020, 14(4): 389-402.
[12]	de Rooij LA, Mastebroek DJ, Ten Voorde N, et al. The microRNA lifecycle in health and cancer[J]. Cancers (Basel), 2022, 14(23): 5748.
[13]	Rishabh K, Khadilkar S, Kumar A, et al. microRNAs as modulators of oral tumorigenesis-a focused review[J]. Int J Mol Sci, 2021, 22(5): 2561.
[14]	Y D, Ramani P, Yuwanati M, et al. microRNA profiling in circulating exosomes in oral squamous cell carcinoma: A systematic review[J]. Cureus, 2023, 15(8): e43235.
[15]	Yoon AJ, Wang S, Kutler DI, et al. microRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality[J]. Head Neck, 2020, 42(8): 1699-1712.
[16]	Li YI, Wang TY, Ding HR, et al. Exosomal microRNA let-7c-5p enhances cell malignant characteristics by inhibiting TAGLN in oral cancer[J]. Oncol Res, 2024, 32(10): 1623-1635. doi: 10.32604/or.2024.048191 pmid: 39308508
[17]	Chen YM, Wang YC, Zhang WB. LINC00342 regulates the PI3K-AKT signaling pathway via the miR-149-5p/FGF11 axis and affects the progression of oral cancer[J]. Discov Oncol, 2024, 15(1): 606.
[18]	Pan ZY, Yang GZ, He H, et al. Identification of cerebrospinal fluid microRNAs associated with leptomeningeal metastasis from lung adenocarcinoma[J]. Front Oncol, 2020, 10: 387. doi: 10.3389/fonc.2020.00387 pmid: 32328453
[19]	Karere GM, Glenn JP, Li G, et al. Potential miRNA biomarkers and therapeutic targets for early atherosclerotic lesions[J]. Sci Rep, 2023, 13: 3467. doi: 10.1038/s41598-023-29074-1 pmid: 36859458
[20]	Lee JH, Massagué J. TGF-β in developmental and fibrogenic EMTs[J]. Semin Cancer Biol, 2022, 86: 136-145. doi: 10.1016/j.semcancer.2022.09.004 pmid: 36183999
[21]	Li X, Chen L, Peng X, et al. Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor[J]. Front Oncol, 2022, 12: 911410.
[22]	Zhang Y, Donaher JL, Das S, et al. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis[J]. Nat Cell Biol, 2022, 24: 554-564. doi: 10.1038/s41556-022-00877-0 pmid: 35411083
[23]	Ebrahimi N, Manavi MS, Faghihkhorasani F, et al. Harnessing function of EMT in cancer drug resistance: A metastasis regulator determines chemotherapy response[J]. Cancer Metastasis Rev, 2024, 43(1): 457-479.
[24]	Li YX, Li B, Yang K, et al. PER3 suppresses tumor metastasis of oral squamous cell carcinoma by promoting HIF-1α degradation[J]. Transl Oncol, 2025, 52: 102258.
[25]	Dillon M, Lopez A, Lin E, et al. Progress on ras/MAPK signaling research and targeting in blood and solid cancers[J]. Cancers (Basel), 2021, 13(20): 5059.
[26]	Bugaj LJ, Sabnis AJ, Mitchell A, et al. Cancer mutations and targeted drugs can disrupt dynamic signal encoding by the Ras-Erk pathway[J]. Science, 2018, 361(6405): eaao3048.